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Targeting tauopathy with engineered taudegrading intrabodies
Gilbert Gallardo1,2* , Connie H. Wong1,2,4, Sara M. Ricardez1,2†, Carolyn N. Mann1,2†, Kent H. Lin1,2,
Cheryl E. G. Leyns1,2,3,5, Hong Jiang1,2,3 and David M. Holtzman1,2,3*

Abstract
Background: The accumulation of pathological tau is the main component of neurofibrillary tangles and other tau
aggregates in several neurodegenerative diseases, referred to as tauopathies. Recently, immunotherapeutic
approaches targeting tau have been demonstrated to be beneficial in decreasing tauopathy in animal models. We
previously found that passive immunotherapy with anti-tau antibody to human tau or expression of an anti-tau
secreted single-chain variable fragment (scFv) in the central nervous system of a mouse model of tauopathy
decreased but did not remove all tau-associated pathology. Although these and other studies demonstrate that
conventional immunotherapeutic approaches targeting tau can influence tau pathogenesis, the majority of
pathological tau remains in the cytosol of cells, not typically accessible to an extracellular antibody. Therefore, we
reasoned targeting intracellular tau might be more efficacious in preventing or decreasing tauopathy.
Methods: By utilizing our anti-tau scFv, we generated anti-tau intrabodies for the expression in the cytosol of
neurons. To enhance the degradation capacity of conventional intrabodies, we engineered chimeric anti-tau
intrabodies fused to ubiquitin harboring distinct mutations that shuttle intracellular tau for either the proteasome or
lysosomal mediated degradation. To evaluate the efficacy in delaying or eliminating tauopathy, we expressed our
tau degrading intrabodies or controls in human tau transgenic mice by adeno-associated virus prior to overt tau
pathology and after tau deposition.
Results: Our results demonstrate, the expression of chimeric anti-tau intrabodies significantly reduce tau protein
levels in primary neuronal cultures expression human tau relative to a non-modified anti-tau intrabody. We found
the expression of engineered tau-degrading intrabodies destined for proteasomal-mediated degradation are more
effective in delaying or eliminating tauopathy than a conventional intrabody in aged human tau transgenic mice.
Conclusion: This study, harnesses the strength of intrabodies that are amendable for targeting specific domains or
modifications with the cell-intrinsic mechanisms that regulate protein degradation providing a new
immunotherapeutic approach with potentially improved efficacy.
Keywords: Alzheimer’s disease, Tauopathy, Immunotherapy, Intrabodies, Tau degradation

Background
Tau was initially identified as a microtubule-associated
protein that subsequently was found to be the main
component of neurofibrillary tangles and other aggregated forms of tau in several neurodegenerative diseases,
referred to as tauopathies [1–4]. These diseases include
several neurodegenerative disorders such as progressive
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supranuclear palsy, corticobasal degeneration, Pick’s disease, and certain forms of frontotemporal dementia. Alzheimer’s disease, the most common cause of dementia,
is a secondary tauopathy that is accompanied by the
presence of amyloid-β pathology. Within the central nervous system (CNS), tau is predominately expressed in
neurons and maintained at higher concentrations within
axons to promote microtubule assembly and stability [5].
The regulation of tau binding to microtubules is mediated by the phosphorylation of serine and threonine residues at sites immediately adjacent to or within the

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Gallardo et al. Molecular Neurodegeneration

(2019) 14:38

microtubule-binding domain (MBD) [2]. Phosphorylation within or around the MBD alters the conformation
of the MBD decreasing its affinity for microtubule binding and liberating tau [6] . The accumulation of hyperphosphorylated, aggregated tau is present in insoluble
paired helical filaments and other structures that result
in tau inclusions.
Emerging evidence now suggests the trans-cellular
propagation of tau pathology mediates the progression of
tauopathy in these diseases [7–9]. Therefore, immunotherapeutic approaches that target extracellular tau could
be a way to decrease the spread of tau pathology. In line
with this notion, recent studies have demonstrated immunotherapy with different anti-tau antibodies prevented
the accumulation of pathological tau in mouse models of
tauopathies10–17. Active vaccination studies in tau transgenic mice targeting aberrant phosphorylated tau protein
have also been shown to reduce tau-associate pathology
and improve behavioral abnormalities [10, 11]. Similar to
active immunotherapies, passive immunotherapy before
or soon after the onset of tauopathy with anti-tau monoclonal antibodies (mABs) also provided some beneficial effects in transgenic tau mice [12–16].
In former studies, we developed and assessed an anti-tau
mAB (HJ8.5) that blocked cellular tau seeding in a biosensor
assay [17–19]. In addition, passive immunization with the
HJ8.5 anti-tau mAB in transgenic mice expressing human
P301S tau (P301S-tg) decreased tau-associated pathology,
slowed disease progression, and improved cognitive deficits
[17–19]. In additional immunotherapy studies, we also generated anti-tau single-chain variable fragments (scFvs) to
evaluate the necessity of the Fc domain, as a potential safety
concern in general for immunotherapies is the development
of adverse effects due to an inflammatory response by IgG
activation of FcγRs on microglia [20, 21]. The expression of
the secreted anti-tau scFvs by adeno-associated virus (AAV)
– mediated gene transfer into the CNS led to a significant
decrease in the accumulation of pathological tau in aged
P301S-tg mice, likely by sequestering extracellular tau [20].
These studies validate the efficacy of anti-tau scFvs and suggest that Fc-dependent microglial mediated tau clearance is
likely not mandatory for anti-tau antibodies to elicit neuroprotective effects. Although these studies support immunotherapeutic approaches with either a secreted anti-tau scFv
or a conventional antibody being sufficient to delay tau
pathogenesis, the majority of pathological tau remains intracellular in the cytosol, making that location of tau likely inaccessible to both cellularly secreted scFvs and full-length
antibodies administered intraperitoneally, subcutaneously,
intravenously, or intracerebroventricularly. Thus, targeting
intracellular tau with anti-tau scFvs expressed intracellularly
in the cytosol (intrabodies) may be more efficacious in preventing tauopathy progression and even in removing existing pathological forms of intracellular tau.
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Advances in recombinant antibody technology have
provided the ability to express intrabodies intracellularly
in the cytosol that function by impairing protein-protein
interactions or neutralizing protein function based on
the epitope targeted. However, the neutralizing mechanisms of conventional intrabodies limit their efficacy
when targeting pathological proteins such as tau, in
which protein interactors that are detrimental remain
unknown and identifying intrabodies that neutralize the
aggregation of intracellular tau is somewhat challenging.
To overcome this potential obstacle and limitation, we
have engineered chimeric anti-tau intrabodies fused to
ubiquitin harboring distinct mutations that make the
intrabody prone for either proteasomal or lysosomal
degradation with the goal of targeting intracellular tau
for degradation. We hypothesized that expression of the
modified tau-degrading intrabodies in neurons would reduce intracellular tau protein levels leading to a greater
neuroprotective effect relative to conventional immunotherapeutic approaches for tauopathies.
In this study, we show the expression of chimeric antitau intrabodies significantly reduces tau protein levels in
primary neuronal cultures expressing P301S human tau
(h-tau) relative to the conventional anti-tau intrabody
containing no modifications. By utilizing AAV2/9-mediated gene transfer, we expressed our anti-tau intrabodies
or controls in P301S-tg mice prior to overt tau pathology. Intriguingly, despite the ability for both chimerically fused anti-tau intrabodies to decrease P301S h-tau
in primary neurons, the expression of anti-tau intrabodies selective for proteasomal mediated degradation in
aged P301S-tg mice displayed effects on preventing the
accumulation of pathological tau. In contrast, expression
of the anti-tau intrabody that targets lysosomalmediated degradation or the conventional anti-tau intrabody were both ineffective in preventing tauopathy.
Additionally, we expressed our anti-tau intrabodies or
controls in aged P301S-tg mice after the onset of tauopathy by AAV-mediated gene transfer. Similar to the effects we observed with the expression of anti-tau
intrabodies prior to overt tauopathy, expressing the antitau intrabody selective for proteasomal mediated degradation displayed effects on decreasing pathological tau in
aged P301S-tg mice.

Methods
Animal model of Tauopathy

The mouse model utilized for the present study were transgenic mice expressing human P301S tau (P301S-tg) purchased from The Jackson Laboratory and bred on a B6C3
background16. P301S mice develop widespread tauassociated pathology that is age dependent primarily in the
hippocampus, parts of the neocortex, amygdala, piriform
cortex, and entorhinal cortex. In this study, male age
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matched P301S mice littermates were analyzed due to the
high variability in tau-associated pathology in aged P301S
female mice [14, 15]. All experiments were conducted
under the institutional guidelines and were approved by the
Institutional Animal Care and Use Committee at Washington University School of Medicine. At the time of endpoint,
mice were anaesthetized before cardiac perfusion with PBS/
heparin followed by brain dissection and immersion in
4%PFA. Following 48 h, the PFA was exchanged with 30%
sucrose and the brain was incubated for an additional 48 h
before freezing with 2-Methylbutane on dry ice and stored
at − 80 °C before sectioned on a microtome (30 μm thickness). Floating sections were kept in 24-well plates with
30% ethylene glycol, 15% sucrose and 0.2 M sodium phosphate at − 20 °C until used.

inhibitors) and 5μg of total protein lysate was subjected to
SDS-PAGE immunoblotting analysis. For proteasomal inhibition, at 72 h post-transfection the cells were treated
with 50 μm MG132 (Sigma Aldrich M7449) for 90 min
followed by collection in standard lysis buffer. For lysosomal inhibition, at 72 h post-transfection the cells were
treated with 500 μm bafilomycin (Sigma Aldrich B1793)
for 6 h followed by collection in standard lysis buffer.
Afterwards, to detect both the expression of each intrabody, controls, and the relative tau protein levels, immunoblots were subjected to anti-HA conjugated HRP (clone
3F10, Roche; 1:10,000) and human tau-specific antibody
anti-HJ8.5 previously characterized14.

AAV injections

We performed neuronal cultures from E17 wild-type mice,
described previously27. For immunofluorescence analysis of
the relative levels of human tau protein, primary cortical
neurons were infected with AAV2/8-synapsin-P301S tau
virus for 6 h on ice. Cells were then pelleted, washed, and
plated onto 24-well tissue culture plates glass cover slips
pre-coated with 10 μg ml− 1 poly-L-lysine (PLL, Sigma,
P2636) at a density of 150,000 cells per well in neurobasal
medium. Following 72 h post-transduction with AAVhuman P301S tau, the primary neuronal cultures were infected with AAV2/9-CBA encoding the various anti-tau
intrabodies and cultured for an additional seven days. For
analysis, primary neuronal cultures were fixed in 4% PFA,
4% sucrose for 10 min followed by permeabilization with
0.3% triton in PBS for 10 min and stained with human specific tau antibody Ht7B (Thermo Fisher, MN1000B).
For measurements of the relative human P301S tau protein in primary neuronal cultures following the expression
of the various anti-tau intrabodies, primary cortical neurons
were infected with AAV2/8-synapsin-P301S tau virus for 6
h on ice. Cells were then pelleted, washed, and plated onto
6-well tissue culture plates pre-coated with 10 μg ml− 1 polyL-lysine (PLL, Sigma, P2636) at a density of 400,000 cells
per well in neurobasal medium. Following 72 h posttransduction with AAV-human P301S tau, the primary
neuronal cultures were infected with AAV2/9-CBA encoding the various anti-tau intrabodies and cultured for an additional seven days. For analysis, 200 μl of standard RIPA
buffer was added to each well for collection of total neuronal
protein lysates followed by sonication. For human tauspecific measurements in neuronal lysates, a SandwichELISA was used. Plates were coated with Tau5 (gift from L.
Binder, Northwestern University, Chicago, Illinois, USA)
and blocked with 4% BSA in PBS. Samples were diluted in
sample buffer and as a detector antibody biotinylated antihtau (clone HT7, Thermo Fisher Scientific MN1000B)
followed by streptavidin-HRP (65R-S104PHRP; Fitzgerald)
was used. All ELISAs were developed with super slow TMB

All intrabodies were cloned into the AAV vector under
the control of the chicken-β-actin (CBA) promoter. All
AAV used in these studies were produced at the Hope
Center Viral Vectors Core at Washington University
School of Medicine. Eight month-old P301S mice were
anesthetized with isofluorane (4% induction and 2.0%
maintenance) followed by bupivacaine (2 mg/kg) administration subcutaneously prior to the incision on the
scalp. Once anesthetized, the hair above the skull was
shaved and swabbed with Betadine for sterilization. The
animal was then placed onto a small animal Kopf stereotaxic apparatus equipped with an anesthetic mask. The
skin was resected just posterior to the eyes to the base
of the skull and the skull is cleaned with sterile artificial
cerebrospinal fluid. The virus was injected unilaterally
into the hippocampus at coordinates bregma: − 2.5 mm
posterior, 2.0 mm horizontal from midline (right), at a
depth of 2.2 mm utilizing a Hamilton syringe (1702RNR)
at 0.5 μl/minute for a final volume of 2.5 μl. The
Hamilton syringe was then left for an additional five minutes and gently withdrawn.
Characterization of intrabodies in 293 t (HEK cells)

Prior to plating HEK cells, plates were coated with 10 μg
ml− 1 poly-L-lysine (PLL, Sigma, P2636) 10 min followed
by brief washes with water. The HEK293t cells were plated
in DMEM supplemented with 10% FBS at a density of 60
K cells/well. Following 24 h HEK293t cells were transiently transfected with Lipofectamine according to the
guidelines of the manufacturer (ThermoFisher). The concentrations of transfected intrabody expressing plasmids
ranged from 0.1μg, 0.5μg, 1.0 μg, and 2.0μg pDNA together with co-transfection of 0.2μg pDNA of a tau expressing plasmid. Following 72 h post-transfection the
HEK293t whole cell lysates were collected in standard lysis
buffer (50 mM Tris-buffer, 150 mM NaCl, 1 mM EDTA,
1% triton and a cocktail of protease and phosphatase

Primary neuronal cultures expressing human tau and the
intrabodies
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substrate solution (Sigma) before reading on a plate reader
at 650 nm.
Immunohistochemistry

Utilizing the free-floating method, we subjected unilaterally
injected AAVs encoding intrabody-K48R, intrabody-K63, conventional intrabody, or AAV-control injected mice brain
sections to pathological tau marker anti-AT8 (phospho-tau
Ser202, Thr205, Thermo Scientific, MN1020B) and for detection of the various intrabodies anti-HA (Vector Laboratories and Bethyl Laboratories, Inc.). Brain sections (30 μm)
were picked that displayed a clear structured cross-section
of the hippocampus, piriform, and entorhinal cortex regions. For quenching auto fluorescence, the sections were
incubatated in sudan black (40 mg in 40 ml of 70% EtOH)
for 10 min followed by washing with 0.03% PBS-Tween.
Nonspecific binding was blocked by PBS 3% BSA, 3% normal goat serum 0.1% Triton X-100. Brain sections were
then incubated with primary antibodies, rabbit anti-HA (1:
1000), and anti-AT8 (1:500) overnight at 4C. Thereafter,
the sections were washed three times in PBS for 10 min
each followed by incubation with anti-streptavidin conjugated 568 (Molecular Probes 1:500), and anti-rabbit conjugated 488 (Molecular Probes 1:500) for 2 h at room
temperature in the dark. Sections were then washed three
times in PBS for 20 min each and mounted with ProLong
Gold anti-fade reagent. Images were taken with an epifluorescence microscope at 4× magnification and quantified
using MetaMorph as previously reported27. For analysis of
p-tau (anti-AT8), the dentate gyrus, granule cell layer,
mossy fibers, CA1, CA2, CA3 regions were traced from a
minimum of 2 sections (300 μm) apart from each other per
mouse using MetaMorph. To determine the percent area
covered per region, we quantified the average ratio of p-tau
(AT8) positive area from the contralateral to ipsilateral side.
To measure total tau levels brain sections from mice
injected unilaterally with AAVs encoding intrabody-K48R,
intrabody-K63, conventional intrabody, or AAV-control
injected were subjected to immunohistochemistry with
human anti-HT7 (Thermo Fischer, MN1000B). Free
floating whole brain sections cut at 30 μm were incubated in .3% H2O2 in TBS for 10 min at room
temperature to quench endogenous peroxidase. Sections
were blocked in 3% milk .25% Triton X-100. Sections
were incubated with primary antibody anti-HT7(1:500)
for 1 h at room temperature. ABC Elite solution (1:400)
was prepared from VECTASTAIN Elite ABC system
(Vector Labs) and sections were incubated in solution
for 1 h at room temperature. Staining was developed for
5 min with DAB plus .01% Nickel and .0005% H2O2. Sections were then dipped in ethanol and Xylene to clear
any excess DAB and mounted with Cytoseal. Images
were captured using the Olympus Nanozoomer 2.0-HT
(Hammatsu). Images were then exported to ImageJ and
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for analysis of total tau, the dentate gyrus, granule cell
layer, mossy fibers, Ca1, Ca2, Ca3, striatum radiatum,
and hippocampal fissure were manually traced from 2
sections per mouse. To determine the percent area covered per region, we quantified the average ratio of tau
positive area from contralateral to ipsilateral side.
Fluorescence in-situ hybridization

For generation of the RNA probe, the anti-tau scFV
plasmid was cloned into the pCR II-TOPO vector using
the TOPO™ TA Cloning™ Kit, Dual Promoter (ThermoFisher 450,640). The plasmid was then digested with
Not1 for 1 h and subsequently purified. The linearized
DNA was then transcribed into RNA in the presence of
DIG-UTP using the DIG RNA Labeling Kit (SP6/T7)
using standard protocol procedures (Sigma-Aldrich (11,
175,025,910 Roche).
Mounted sections were incubated with 1 mg/mL pepsin in 0.2 M HCl at 37 °C for 7 min for antigen retrieval
followed by three washes of 5 min in PBS. The sections
were then incubated twice in 0.1 M phosphate buffer
(PB) for 10 min, twice in 0.75% glycine in 0.1 M PB for
15 min, and once in 0.3% Triton X-100 in 0.1 M PB for
20 min, followed by a 5 min wash in PB. For cell
permeabilization the sections were incubated for 30 min
at 37 °C in 1 M Tris-Cl 0.5 M EDTA buffer containing
0.5 μg/mL proteinase K followed by a single wash in
0.75% glycine for 5 min and one wash in 5X SSC for 5
min. Following the proteinase K digestion, the sections
were incubated in hybridization buffer (5X SSC buffer
containing 50% formamide, 1x Denhardts, 10 mg/ml salmon sperm DNA, 12.5 mg E. coli tRNA) for 2 h at room
temperature. The RNA probe was diluted (1uL/100uL)
in hybridization buffer, heated at 80 °C for 5 min prior to
applying to the sections which were placed in a vertical
chamber humidified with 5X SSC in 50% formamide
overnight at 65 °C. The next day, the slides were submerged in pre-warmed 5X SSC for 5 min at 65 °C
followed by 3 washes in 0.2% SSC for 30 min each at
65 °C. Sections were then blocked with 0.25% PBSTriton X-100 5% normal goat serum for 30 min at room
temperature followed by incubating with the antiphospho-tau mAB (AT8 1:500) in 3% BSA-PBS .1% triton overnight at 4 °C. Following three consecutive
washes in PBS for 10 min. Fluorescently labeled secondary antibodies were diluted 1:500 in 3% BSA-PBS and
applied to the sections for 2 h at room temperature.
After three 20 min washes with PBS, sections were coverslipped with Prolong Gold with DAPI (Invitrogen).
Statistical analysis

Blinding and randomization was performed on all analysis.
All graphs represent means ± SEM. Statistical analysis was
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performed with GraphPad Prism 5.01 using one-way
ANOVA with Tukey’s multiple comparison.

Results
Engineering anti-tau intrabodies designed for proteasome
or lysosomal tau-mediated degradation

We first set out to determine if shuttling our anti-tau
intrabody, derived from anti-tau antibody HJ8.5, for either proteasomal or lysosomal degradation pathways by
the ubiquitin system substantially decreases intracellular
tau protein levels. Ubiquitin is a highly conserved small
regulatory protein that is covalently attached to lysine
residues of target proteins. The ubiquitination of target
proteins may regulate either their cellular localization,
protein interactions, or degradation that is dependent on
either monoubiquitination or polyubiquitination. The
polyubiquitination occurs at one of seven lysine residues
of ubiquitin, most predominantly at the lysine-48 (K48)
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or lysine-63 (K63). A K48-linked polyubiquitin chain targets proteins for destruction by shuttling them to the
26S proteasome (Fig. 1a) [22]. In contrast, K63-linked
polyubiquitination induces protein degradation predominantly in the lysosome (Fig. 1a) [23–25]. To explore the
potential of shuttling intracellular tau to the proteasome
for degradation, we engineered a chimeric anti-tau intrabody fused to ubiquitin harboring a K63R mutation favoring polyubiquitination at the K48 site. Conversely, to
determine the efficiency of delivering intracellular tau
for lysosomal-mediated degradation, we generated a second chimeric intrabody fused to ubiquitin harboring a
K48R mutation favoring polyubiquitination at K63. For
detection of our anti-tau intrabody, a C-terminal human influenza hemagglutinin (HA) tag was inserted. Next, we
transfected HEK293t expressing h-tau with either a conventional anti-tau intrabody containing no distinct tags, or our
modified proteasome targeting intrabody (intrabody-K63R),

Fig. 1 Engineering chimeric tau-degrading intrabodies fused to ubiquitin for proteasome or lysosomal-mediated degradation. a Diagram depicts
that K48-linked polyubiquitin tau-intrabodies shuttle tau for proteasome degradation, whereas, K63-linked polyubiquitin tau-intrabodies shuttle
tau for lysosomal degradation. b Immunoblotting analysis of HEK293t cell lysates co-expressing h-tau together with either a conventional anti-tau
intrabody or the anti-tau intrabodyK48R revealed the chimeric anti-tau intrabody fused to ubiquitin harboring a K48R mutation decreased tau
protein levels relative to the conventional intrabody or control. Protein levels are relative to actin. The expression of the anti-tau intrabodyK48R
also revealed a lower band that potentially corresponds to a cleaved form of the chimeric intrabody. c Immunoblotting analysis of HEK293t cell
lysates co-expressing h-tau together with either a conventional anti-tau intrabody or the anti-tau intrabodyK63R revealed the chimeric anti-tau
intrabody fused to ubiquitin harboring a K63R mutation decreased tau protein levels relative to the conventional intrabody and control. Similarly,
expression of the anti-tau intrabodyK63R also revealed a lower band that potentially corresponds to a cleaved form of the chimeric intrabody. d
Immunoblotting analyses of HEK293t cell lysates co-expressing h-tau together with either a conventional anti-tau intrabody, anti-tau intrabodyK63R
or anti-tau intrabodyK48R following proteasomal (MG132) or lysosomal (Baf) inhibition
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lysosomal targeting (intrabody-K48R) and control empty vector. At 72 h post-transfection, whole protein lysates were
subjected to immunoblotting analysis for h-tau protein
(anti-h-tau) and the intrabody (anti-HA). This revealed a
decrease in h-tau protein levels upon the expression of both
anti-tau intrabody-K48R and intrabody-K63R relative to the
conventional unmodified anti-tau intrabody or empty vector control (Fig. 1b-c). The anti-tau intrabodies-K48R and
-K63R
were much less abundant relative to the conventional
anti-tau intrabody implicating these intrabodies are readily
degraded together with h-tau.
To demonstrate the chimeric anti-tau intrabodies fused to
ubiquitin harboring mutations at either K48 or K63 predominately target h-tau for proteasomal or lysosomal degradation, HEK293t cells co-expressing the various tau
intrabodies with h-tau were treated with 50 μM MG132
(proteasome inhibitor) or 500 μM bafilomycin (lysosome inhibitor) (Fig. 1d). The decrease in h-tau protein levels upon
expression of the anti-tau intrabody-K48R was predominantly
blocked by bafilomycin a classical lysosome inhibitor, with
no effects on tau protein levels with inhibition of the
proteasome by MG132 (Fig. 1d). In contrast, the decrease in
h-tau protein levels upon expression of the anti-tau intrabody-K63R was predominantly blocked by inhibition of the
proteasome with MG132 and too a much lesser extent following lysosomal inhibition with bafilomycin (Fig. 1d).
These analyses support anti-tau intrabodies harboring mutations at either K48 or K63 predominantly target h-tau for either proteasomal or lysosomal degradation.
We next determined if the chimerically fused intrabodies are polyubiqutinated by expressing the intrabodies in
HEK293t cells followed by immunoprecipitation with an
anti-HA antibody. The resultant intrabodies were then
subjected to immunoblotting with anti-ubiquitin revealing
that both chimerically fused intrabodies are polyubiquitinated (Additional file 1: Figure S1). Additionally, we determined if h-tau was polyubiquitinated following the
expression of the chimeric intrabodies by immunoprecipitating h-tau from HEK293t cell lysates co-expressing the
various anti-tau intrabodies or h-tau only. The resultant
tau protein was then subjected to immunoblotting with
anti-ubiquitin revealing little polyubiquitin following the
co-expression of the chimerically fused intrabodies to ubiquitin. The small amount of polyubiquitin may potentially
reflect the co-IP of the intrabodies which are polyubiquitinated (Additional file 1: Figure S1). These analyses suggest
the chimerically fused anti-tau intrabodies are polyubiquitinated and shuttle h-tau for degradation.
Expression of tau-degrading intrabodies in primary
neurons expressing human tau protein reduce tau
protein levels

The analyses in HEK293t cells demonstrated chimerically
fused intrabodies with ubiquitin harboring lysine mutations
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that designate them for either proteasome or lysosomalmediated degradation decreases intracellular h-tau protein
levels. We next set out to determine the efficiency of degrading intracellular h-tau in neurons following AAVmediated gene transfer of either the anti-tau intrabody-K48R,
intrabody-K63R, or the conventional intrabody containing no
targeting tags. In previous studies, we demonstrated that
primary neuronal cultures transduced with AAVs encoding
mutant P301S-htau for six hours before plating leads to
stable expression of P301S-htau in neurons at 72 h post
plating [26]. This paradigm enables the evaluation of the
relative amount of P301S-htau protein following the coexpression of the anti-tau intrabodies and controls. Primary
wild-type neurons expressing P301S-htau under a synapsin
promoter were cultured for three days, followed by transduction with AAVs encoding each of the tau-degrading
intrabodies or the conventional non-modified anti-tau
intrabody driven by a chicken β-actin promoter. To assess
the relative P301S-htau protein levels upon expression of
the various intrabodies, the primary neurons were fixed at
DIV10 for analysis by immunofluorescence (IF) (Fig. 2a).
The IF analysis for P301S-htau protein revealed a decrease
in P301S-htau protein levels throughout the dendrites,
axons and cell bodies of neurons expressing either the conventional anti tau intrabody, anti-tau intrabodyK48R, or
intrabodyK63R relative to the AAV-control. To complement
the h-tau IF analysis, we determined the amount of human
P301S-htau protein from total neuronal lysates by ELISA.
Wild type neurons expressing P301S h-tau were transduced
with the various AAV-intrabodies and controls followed by
harvesting neuronal lysates at DIV10 for ELISA analysis.
ELISA measurements for h-tau protein from total lysates
revealed a statistically significant decrease in P301S-htau
protein levels following the expression of both the
chimeric ubiquitin fused anti-tau intrabodies (K48R and
K63R) relative to the control AAV. Analysis of the nonmodified conventional intrabody revealed a nonsignificant trend toward lower tau protein levels relative to
the control AAV (Fig. 2b). These analyses demonstrate
that certain anti-tau intrabodies decrease intracellular tau
protein levels in neurons.
Expression of tau-degrading intrabodies in P301S-tg mice
prior to overt tauopathy

We have hypothesized the expression of anti-tau intrabodies in neurons will decrease intracellular tau protein
levels leading to a greater effect relative to conventional
immunotherapeutic approaches for tauopathies. Therefore, following the validation that certain anti-tau intrabodies significantly reduced intracellular h-tau protein levels
in primary neurons, we set to evaluate the efficacy of the
anti-tau intrabodies on delaying or decreasing tauopathy
in aged P301S-tg mice. P301S-tg mice develop agedependent tauopathy that begins at ~ 5–6 months of age
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Fig. 2 Expression of tau-degrading intrabodies decreases human tau in neurons. a Representative images of primary neurons co-expressing
P301S-htau and the various anti-tau intrabodies. Expression of the conventional anti-tau intrabody, intrabody-K48R or the intrabody-K63R displayed a
marked decrease in h-tau protein levels relative to the AAV-control; scale bar 50 μm. b P301S-htau protein quantification by tau ELISA in primary
neurons co-expressing the various intrabodies revealed a significant decrease in h-tau protein levels upon expression of each tau-degrading
intrabody relative to the AAV-controls. Expression of the conventional anti-tau intrabody displayed an non-significant decrease in h-tau protein
relative to the AAV-control. Results are representative of three independent experiments, all data are expressed as mean ± s.e.m. and one-way
ANOVA was performed with Tukey’s Multiple Comparison. *p < 0.05

displaying moderate pathological tau accumulation in the
hippocampus as assessed with an anti-phosphorylated tau
antibody AT8 (Additional file 1: Figure S2). AT8 targets
phosphorylated tau (p-tau) at residues Ser202 and Thr205
that is present in aggregated forms of tau, including paired
helical filaments and in other pathological conformations.
To determine the effects of expressing the different antitau intrabodies prior to overt tauopathy, we unilaterally
injected AAVs encoding either the chimeric anti-tau intrabodies fused to ubiquitin (intrabody-K48R, intrabody-K63),
conventional intrabody, or AAV-control into the 6 month
old P301S-tg mice (n = 4–7 per condition). This time
point is consistent with early disease displaying a minimal
deposition of p-tau in the hippocampus (Additional file 1:
Figure S1). Following 12 weeks post-injection, the mice
were euthanized for histopathological analysis. To validate
the expression of each anti-tau intrabody we subjected the
cohort of 9.5 month old P301S-tg mice to immunofluorescence analysis with anti-HA. Although, anti-HA staining revealed the presence of the conventional anti-tau intrabody
protein containing no targeting tags throughout the dentate
gyrus mossy fiber regions of the hippocampus, detection of
either the intrabody-K48R or intrabody-K63R were much less
evident (Fig. 3a). The low protein detection of the taudegrading intrabodies parallels our initial characterization in
cell culture analysis suggesting a rapid degradation of these
anti-tau intrabodies in vivo (Fig. 1). Therefore, to validate
the expression of each anti-tau intrabody, we performed
fluorescence in situ hybridization (FiSH) utilizing a probe

that extended the length of the variable regions of the heavy
and light chains of the anti-tau intrabody (Fig. 3b). This analysis revealed expression of each anti-tau intrabody unilaterally in the dentate gyrus, CA2, and CA3 regions but not in
the CA1 cell layer of the hippocampus of 9.5 month old
P301S-tg mice.
Expression of tau-degrading intrabodies prior to overt
tau pathology prevented tauopathy in aged P301S-tg
mice

Upon validating the expression for each intrabody unilaterally in the hippocampus of aged P301S-tg mice, we next
assessed the efficiency for the tau-degrading intrabodies to
prevent or delay the accumulation of pathological tau. At
9.5 months old, P301S-tg mice displayed a substantial
amount of p-tau in the hippocampus (Additional file 1:
Figure S2) To determine the percent decrease of pathological tau following the expression of the various anti-tau
intrabodies at early-disease, an average ratio of p-tau positive staining from the contralateral (non-injected) side to
the ipsilateral (injected region) was measured within the
dentate gyrus, granule cells, mossy fibers, CA1, CA2, and
CA3 regions of the hippocampus. This analysis revealed a
statistically significant decrease in pathological tau within
the ipsilateral CA2, dentate gyrus, mossy fibers, and the
granule cell layer expressing the chimeric tau-degrading
intrabody fused to ubiquitin harboring a K63R mutation
relative to the control AAV (Fig. 4a-b). In contrast, measurements for the accumulation of pathological tau in the
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Fig. 3 Immunofluorescence and fluorescence in situ analysis of anti-tau intrabody expression in aged P301S-tg mice. a Representative images of
anti-HA for protein expression of the various anti-tau intrabodies in 9.5-month-old P301S-tg mice. Immunofluorescent detection of HA reveals
clear-cut evidence of the non-targeting anti-tau intrabody within the ipsilateral hippocampus, whereas there was little to no immunofluorescence
signal with the modified anti-tau intrabodies. Arrowhead indicating the injection site within the dentate gyrus (dg). b Representative images of in
situ hybridization in 9.5-month-old P301S-tg mice validated the expression of the mRNA of the various anti-tau intrabodies within the
hippocampus ipsilateral to the AAV injection. Scale bar 200 μM

CA1 hippocampal cell layer that lack expression of the
intrabodies indicated a comparable percent area covered
by tau pathology within the ipsilateral and contralateral
hippocampus for all intrabodies (Fig. 4a-b). Intriguingly,
the expression of either the conventional anti-tau intrabody
or the intrabody fused to ubiquitin harboring a K48R mutation was ineffective in delaying or eliminating tauopathy in
in vivo which contrasted with our data in HEK293t cells
and primary neuronal cultures (Figs. 1 and 2).
In additional studies, we determined the total tau protein
levels following the expression of the various anti-tau intrabodies at early-disease, an average ratio of total human tau
positive staining (anti-HT7) from the contralateral (noninjected) side to the ipsilateral (injected region) was measured within the dentate gyrus, granule cells, mossy fibers,
CA1, CA2, and CA3 regions of the hippocampus. This analysis revealed a statistically significant decrease in h-tau
within the ipsilateral CA2 following the expression of both
the chimeric tau-degrading intrabody fused to ubiquitin
harboring a K63R mutation. Additionally, there was a nonsignificant trend toward lowering of h-tau levels within the
CA1, CA3, mossy fibers and dentate gyrus following the expression of the anti-tau intrabody harboring a K63R mutation (Additional file 1: Figure S3).
Collectively, these analyses suggest intrabodies that
predominantly target tau for proteasomal degradation
are more proficient in degrading pathological tau relative

to conventional intrabodies in vivo in human tau transgenic mice.
Expression of tau-degrading intrabodies reduce
tauopathy in aged P301S-tg mice

We next assessed the efficiency for our tau-degrading
intrabodies to eliminate or decrease tau pathology after
extensive tauopathy is already deposited in the hippocampus of P301S-tg mice (mid-disease). At 8.5 months P301Stg mice display substantial deposition of pathological tau
throughout the hippocampus predominantly in the dentate gyrus mossy fibers (Additional file 1: Figure S2).
Therefore, we unilaterally injected AAVs encoding either
anti-tau intrabody-K48R, intrabody-K63R, conventional intrabody, or AAV-control into the dentate gyrus at 8.5
months of P301S-tg mice (n = 6–8 per condition). Six
weeks post-injection, the mice were euthanized for histopathological analysis to assess the expression of each antitau intrabody and the effects on tau pathology.
Similar to what we observed with injections at 6
months of age, prior to overt tau pathology (Fig. 3), antiHA staining revealed protein expression for the conventional anti-tau intrabody containing no targeting tags
throughout the dentate gyrus-mossy fibers of the
hippocampus (Additional file 1: Figure S4a). Whereas,
anti-HA staining of either the intrabody-K48R or intrabody-K63R were much less evident (Additional file 1:
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Fig. 4 Tau-degrading intrabodies prevent tauopathy at early-disease in P301S-tg mice. a Representative images of pathological tau accumulation
as seen with AT8 staining in 9.5 month-old P301S-tg mice following the expression of anti-tau intrabodies prior to overt tau pathology (earlydisease). b AAV-control displayed an increase in pathological tau accumulation in the ipsilateral hippocampal side. Expression of the conventional
anti-tau intrabody displayed a non-significant increase in pathological tau accumulation in the dentate gyrus, granule cells, mossy fibers and CA2
region of the ipsilateral relative to the contralateral hippocampus. Expression of the chimeric tau-degrading intrabody fused to ubiquitin
harboring a K48R mutation prone for lysosomal-meditated degradation displayed a non-significant increase in pathological tau accumulation in
the granule cells, CA1 and CA3 region of the ipsilateral relative to the contralateral hippocampus. Expression of the chimeric tau-degrading
intrabody fused to ubiquitin harboring a K63R mutation prone for proteasome-mediated degradation displayed a significant decrease in
pathological tau accumulation in the ipsilateral hippocampal dentate gyrus, granule cells and mossy fibers ipsilateral relative to the contralateral
hippocampus. Scale bar 200 μM. Quantification (n = 4–7) of pathological tau from the ipsilateral relative to the contralateral dentate gyrus. All
data are mean ± s.e.m. one-way ANOVA with Tukey’s Multiple Comparison. *p < 0.05, **p < 0.01

Figure S4a). Nonetheless, FiSH analysis validated the expression of each anti-tau intrabody unilaterally in the
dentate gyrus, CA2, and CA3 regions but not in the
CA1 cell layer of the hippocampus of P301S-tg mice
(Additional file 1: Figure S4b).
Following the validating for the expression for each intrabody unilaterally in the hippocampus of aged P301S-tg mice,
we next assessed the efficiency for the tau-degrading intrabodies to eliminate or decrease related tauopathy. Two hippocampal sections from each P301S-tg mouse expressing
the various intrabodies were subjected to immunohistological analysis for p-tau (AT8) and quantified for the percent
decrease of pathological tau within the dentate gyrus, granule cells, mossy fibers, CA1, CA2, and CA3 regions of the
hippocampus as previously. This analysis revealed a statistically significant decrease in pathological tau within the ipsilateral dentate gyrus and mossy fibers expressing the
chimeric tau-degrading intrabody fused to ubiquitin harboring a K63R mutation relative to the AAV-control (Fig. 5a-b).

Measurements for the accumulation of pathological tau in
the CA1 hippocampal cell layer that lack expression of the
tau intrabodies indicated a comparable percent area covered
by tau pathology within the ipsilateral and contralateral
hippocampus (Fig. 5a-b). In line with our analyses at an
early-disease state when treatment was started (Fig. 4), the
expression of the conventional anti-tau intrabody and the
intrabody-K48R at a mid-disease stage were ineffective in
eliminating or decreasing tauopathy in vivo in P301S-tg
mice (Fig. 5a-b). Collectively, these analyses further validate tau-degrading intrabodies destined for proteasomal
mediated degradation are more proficient in degrading
pathological tau relative to a conventional intrabody in
P30S-tg mice.

Discussion
By utilizing ubiquitin, we have engineered anti-tau intrabodies that are prone to target tau for either the proteasome or lysosomal-degradation to identify the most
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Fig. 5 Tau-degrading intrabodies eliminate tauopathy at mid-disease in P301S-tg mice. a. Representative images of pathological tau
accumulation as seen with AT8 staining in 9.5 month-old P301S-tg mice following the expression of anti-tau intrabodies after tauopathy
deposition (mid-disease). b AAV-control displayed an increase in pathological tau accumulation in the ipsilateral hippocampal side. Expression of
the conventional anti-tau intrabody displayed a non-significant increase in pathological tau accumulation in the dentate gyrus, granule cells,
mossy fibers and CA2 ipsilateral relative to the contralateral hippocampus. Expression of the chimeric tau-degrading intrabody fused to ubiquitin
harboring a K48R mutation prone for lysosomal-meditated degradation displayed a non-significant increase in pathological tau accumulation in
the granule cells, CA1 and CA3 regions of the ipsilateral relative to the contralateral hippocapus. Expression of the chimeric tau-degrading
intrabody fused to ubiquitin harboring a K63R mutation prone for proteasome-mediated degradation displayed a significant decrease in
pathological tau accumulation in the hippocampal dentate gyrus, granule cells and mossy fibers in the ipsilateral relative to the contralateral
hippocampus. Scale bar 200 μM. Quantification (n = 6–9) of pathological tau from the contralateral to the ipsilateral dentate gyrus. All data are
mean ± s.e.m. one-way ANOVA with Tukey’s Multiple Comparison. *p < 0.05, **p < 0.01

proficient mechanism for reducing tauopathy. We demonstrate an anti-tau intrabody chimerically fused to ubiquitin harboring a mutation prone for proteasome
degradation significantly reduced tauopathy in aged
P301S-tg mice prior to overt tauopathy (early disease)
and after substantial pathological tau deposition (late
disease) relative to the conventional intrabody and controls. Follow up studies should aim at evaluating the global expression of the tau-degrading intrabodies and their
efficacy in preventing brain atrophy and behavioral abnormalities of aged P301S-tg mice.
Intriguingly, despite all three intrabodies displaying the
ability to reduce tau in HEK293t cells and primary neuronal cultures, the chimeric intrabody fused to ubiquitin
harboring a mutation prone for lysosome-mediated degradation failed to prevent tauopathy in aged P301S mice
after the onset of disease. One possibility is that the decreased efficacy seen with the K48R mutation may stem
from the fact that polyubiquitination at K63 has been

shown to display a variety of cellular functions in addition
to lysosomal degradation that includes DNA repair and
internalization of plasma membrane proteins [27–29].
Thus, the ubiquitin harboring a K48R mutation in vivo
may be less prone for lysosomal degradation or perhaps
the pathophysiological events leading to tauopathy decreases the efficiency of this particular intrabody’s ability
to allow for targeted lysosomal degradation [30, 31]. Alternatively, the anti-tau intrabody-K48R is rapidly degraded
before binding to tau protein leading to a decrease in efficacy. Future studies should aim at evaluating whether targeting other tau mutants for proteasomal degradation also
display a higher efficacy relative to the lysosomal degradation with our tau degrading intrabodies.
Bi-functional intrabodies directed toward the proteasome targeting other proteinopathies (e.g. Huntingtin
and TAR DNA-binding protein 43) have been proposed
in previous studies by fusing a PEST domain to certain
scFv [32, 33]. Proteins with PEST domains display a
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short half-life, thus intrabodies fused to a PEST domain
mimic a short half-life and are rapidly degraded. Although, conceptually PEST-intrabodies decreased the
targeted pathological protein in these prior studies, the
effects were demonstrated only in cellular culture
models by the co-expression of the intrabody with the
pathological protein [32, 33]. In the current study, we
evaluated a disconnect between the ability for a chimeric
intrabody fused to ubiquitin harboring a mutation prone
for lysosome-mediate degradation to reduce tau protein
levels in primary neuronal cultures/HEK293t cells and
its inability to reduce tauopathy in vivo in aged P301S-tg
mice. This disconnect illustrates that although cell culture models are important for rational design, the complexity of in vivo models do not always translate in vivo.
Therefore, the therapeutic potential or the extent to
which PEST-intrabodies prevent proteinopathies in vivo
in aging mammalian models of proteinopathies remains
largely unknown. Moreover, the efficiency for PESTintrabodies to reduce the proteinopathy after the onset
of disease also remains a critical question that is unanswered and is important for a thorough evaluation.

Conclusions
Compelling evidence from several studies has demonstrated immunotherapies targeting h-tau are neuroprotective in mouse models of tauopathies [10–17]. However,
conventional immunotherapeutic approaches have some
limitations that may preclude their full potential when targeting tauopathy. Particularly, immunotherapy by most
approaches is limited to targeting extracellular pathological proteins, whereas the majority of pathological tau
remains intracellular in the cytosol where it is not likely to
be able to interact with anti-tau mAB or secreted scFvs. In
the current study, we describe a new immunotherapeutic
approach that demonstrates potential for overcoming this
limitation by targeting the degradation of h-tau intracellularly in the cytosol with tau-degrading intrabodies following AAV-mediated gene transfer into the brain.
Combining this approach with the recent advances of
AAV-mediated gene transfer that provides globalneuronal transduction in the adult mouse CNS by intravenous administration may provide a feasible approach for
potential long-term treatment of tauopathies.
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